The raised guidance and continued improvement in adjusted EBITDA suggest Cryoport is on a path to profitability. Monitor the Q4 2026 launch of the Santa Ana Global Supply Chain Center and any further BLA/MAA filings from clients, as these could drive additional commercial CGT revenue.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $19.10entry
- T+1 · 8d ago +7.17%α +4.81% · $20.47
- T+5 · 4d ago +4.14%α +1.54% · $19.89
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Cryoport reported Q3 2026 revenue of $50.4 million, up 13% year-over-year, and a GAAP net loss per share of $0.23, narrower than the prior year's $0.28 loss. The company raised its full-year 2026 revenue guidance to $196M-$200M, above the prior range of $192M-$196M, reflecting continued momentum in commercial cell and gene therapy support and Life Sciences Services growth.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $50.4M, up 13% year-over-year from $44.6M
- Commercial CGT revenue grew 28% YoY to $10.1M
- Life Sciences Services revenue $29.2M, up 16% YoY
- Life Sciences Products revenue $21.2M, up 9% YoY
- GAAP net loss per share $0.23 vs $0.28 in Q3 2025
- Adjusted EBITDA from continuing operations improved to negative $0.2M from negative $2.1M
- Full-year 2026 revenue guidance raised to $196M-$200M from $192M-$196M
- Supporting 810 global clinical trials and 24 commercially approved CGTs as of September 30, 2026
Financial Impact
Revenue growth of 13% YoY to $50.4M; guidance raised by $4M at midpoint to $198M; adjusted EBITDA loss narrowed by $1.9M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Life Sciences Services | $29.2M | +16.0% |
| Life Sciences Products | $21.2M | +9.0% |
Risk Factors
- Company remains unprofitable on a GAAP basis with a net loss from continuing operations of $8.5M
- Dependence on client regulatory approvals for commercial CGT revenue growth
- Execution risk related to new Global Supply Chain Center openings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Data (Synthetic) | 0001104659-26-123381 |
Track record
10 reports on CYRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $19.89 Now $19.80 −0.45% settles Nov 20
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $20.56 Now $19.80 −3.70% settles Nov 18
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $20.74 Now $19.80 −4.53% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $19.10 to $19.89 Now $19.80 +3.66% ▲ +4.14% +1.54% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $17.83 to $18.29 Now $19.80 +11.05% ▲ +2.58% +1.87% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 5/10 Entry $15.25 to $17.13 Now $19.80 +29.84% ▲ +12.33% +13.70% vs SPY
- Jun 21, 202621w ago Institutional Cluster Mixed 4/10 Entry $14.77 to $16.00 Now $19.80 +34.06% ▲ +8.33% +10.40% vs SPY
- Jun 12, 202622w ago Insider Cluster Neutral 4/10 Entry $14.83 to $14.77 Now $19.80 +33.51% ▼ −0.40% +0.98% vs SPY
- Mar 16, 202635w ago Insider Cluster Neutral 3/10 Entry $8.00 to $8.15 Now $19.80 +147.50% ▲ +1.88% +3.92% vs SPY
- Mar 16, 202635w ago Insider Cluster Neutral 4/10 Entry $8.00 to $8.15 Now $19.80 +147.50% ▲ +1.88% +3.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers